Citadel Advisors
CRVS icon

Citadel Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Citadel Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.96M Buy
202,400
+27,400
+16% +$437K ﹤0.01% 5291
2025
Q4 		$1.35M Buy
175,000
+108,200
+162% +$853K ﹤0.01% 6754
2025
Q3 		$492K Buy
66,800
+28,600
+75% +$146K ﹤0.01% 9178
2025
Q2 		$153K Sell
38,200
-66,500
-64% -$242K ﹤0.01% 10939
2025
Q1 		$333K Sell
104,700
-56,500
-35% -$266K ﹤0.01% 9354
2024
Q4 		$862K Buy
161,200
+135,400
+525% +$1.01M ﹤0.01% 7366
2024
Q3 		$136K Buy
25,800
+10,400
+68% +$37.3K ﹤0.01% 10689
2024
Q2 		$28K Buy
15,400
+8,700
+130% +$16.2K ﹤0.01% 12336
2024
Q1 		$11.9K Sell
6,700
-29,500
-81% -$61.6K ﹤0.01% 13379
2023
Q4 		$63.7K Buy
36,200
+19,100
+112% +$27.9K ﹤0.01% 11514
2023
Q3 		$25K Sell
17,100
-4,500
-21% -$9.52K ﹤0.01% 12436
2023
Q2 		$49.5K Buy
+21,600
New +$44.9K ﹤0.01% 11813
2023
Q1 		– Sell
-1,100
Closed -$935 – 14822
2022
Q4 		$935 Buy
+1,100
New +$973 ﹤0.01% 14557
2022
Q3 		– Sell
-17,700
Closed -$18K – 12749
2022
Q2 		$18K Sell
17,700
-7,300
-29% -$8.95K ﹤0.01% 12436
2022
Q1 		$41K Sell
25,000
-18,200
-42% -$33.3K ﹤0.01% 12919
2021
Q4 		$104K Sell
43,200
-128,800
-75% -$500K ﹤0.01% 12680
2021
Q3 		$832K Buy
172,000
+144,500
+525% +$428K ﹤0.01% 8597
2021
Q2 		$73K Sell
27,500
-24,700
-47% -$68K ﹤0.01% 13128
2021
Q1 		$161K Buy
52,200
+37,800
+263% +$137K ﹤0.01% 11958
2020
Q4 		$51K Buy
+14,400
New +$58K ﹤0.01% 10558

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors's CRVS Position: Q1 2026 in Review

Citadel Advisors increased its Corvus Pharmaceuticals (CRVS) stake by 113% in Q1 2026, buying an estimated $3.74M and bringing the position to 442,522 shares worth $6.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3929.

Citadel Advisors first reported a position in CRVS in Q3 2018 and has held it in 18 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Citadel Advisors held 442,522 shares of Corvus Pharmaceuticals worth $6.47M as of Q1 2026.
  • Citadel Advisors bought 234,340 Corvus Pharmaceuticals shares in Q1 2026, an estimated $3.74M.
  • Corvus Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3929 holding.
  • Citadel Advisors first reported a position in Corvus Pharmaceuticals in Q3 2018 and has held it in 18 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.